Patients with type 2 diabetes mellitus (T2DM) are at significantly increased risk for the development of coronary artery disease (CAD) (1-4). Several complex and interrelated metabolic abnormalities in these patients are related directly to CAD risk. Among these is a diabetic dyslipidemia that includes increased blood levels of plasma VLDL-triglycerides (TGs), low levels of plasma high density lipoproteincholesterol (HDL-C), abnormalities in the composition of LDL, and increased levels of apolipoprotein B (apoB) (5-8). Although multiple abnormalities in lipid and lipoprotein metabolism likely play important roles in the pathophysiology of diabetic dyslipidemia, overproduction of apoB-lipoproteins appears to be a central component (9-12).
Patients with type 2 diabetes mellitus (T2DM) are at significantly increased risk for the development of coronary artery disease (CAD) (1) (2) (3) (4) . Several complex and interrelated metabolic abnormalities in these patients are related directly to CAD risk. Among these is a diabetic dyslipidemia that includes increased blood levels of plasma VLDL-triglycerides (TGs), low levels of plasma high density lipoproteincholesterol (HDL-C), abnormalities in the composition of LDL, and increased levels of apolipoprotein B (apoB) (5) (6) (7) (8) . Although multiple abnormalities in lipid and lipoprotein metabolism likely play important roles in the pathophysiology of diabetic dyslipidemia, overproduction of apoB-lipoproteins appears to be a central component (9) (10) (11) (12) .
The HMG-CoA reductase inhibitors, or statins, are currently the most efficacious medications for reducing LDL-C levels. Statins have been shown to reduce morbidity and mortality from CAD in both primary and secondary prevention trials (13) (14) (15) . Several studies have demonstrated that statins also decrease CAD events in patients with diabetes (16) (17) (18) (19) . Studies of the effect of statins on LDL-C have found that VLDL-TG and VLDL-C levels are also decreased, particularly when high doses of statins are used (20) . Indeed, most studies have shown that levels of all apoB-lipoproteins are reduced by statin therapy. These findings have raised important questions regarding the mechanisms by which statins decrease plasma lipids. Inhibition of cholesterol synthesis leads to increased levels of LDL receptors, particularly in the liver (21, 22) , and this is consistent with an increased fractional clearance rate (FCR; a measure of the efficiency with which a lipoprotein is cleared from plasma) of LDL-apoB observed during statin treatment of patients with familial hypercholesterolemia (23) . However, the basis for lower VLDL levels is less clear (24) . Although increased fractional clearance of VLDL by statininduced hepatic LDL receptors might account for the lower plasma VLDL concentrations seen, reduced production rates (PRs) of VLDL-apoB and -TG (PR will be used to represent the secretion of apoB and TG from the liver under the conditions of our studies) have also been demonstrated in several studies of statin therapy in patients with increased plasma VLDL concentrations. In a study in which we treated patients with combined hyperlipidemia with lovastatin, we observed a decrease in total production of apoBlipoproteins by the liver (25) and reductions in VLDL-TG secretion (26) . However, a review of the literature, with all but one study conducted in patients with dyslipidemia without T2DM, reveals inconsistent effects of statins on apoB-lipoprotein secretion. In the only study of the effects of statin treatment on apoB metabolism in patients with T2DM, Ouguerram et al. (27) observed both decreased VLDL-apoB secretion into plasma and normalization of a baseline low FCR of LDL in patients with T2DM. That study did not measure VLDL-TG metabolism. Because overproduction of apoB-lipoproteins is characteristic of the dyslipidemia of diabetes, we undertook a randomized, double-blind, crossover study of the effects of high-dose simvastatin therapy on the PRs and FCRs of VLDL-, intermediate density lipoprotein (IDL)-, and LDL-apoB and VLDL-TG in patients with T2DM.
METHODS

Patients
The clinical characteristics of the five patients who were studied are presented in Table 1 . All subjects had diet-or oral agenttreated T2DM and had been referred to our lipid clinic for evaluation of hyperlipidemia. Lipid inclusion criteria included a TG of у 200 mg/dl but Ͻ 600 mg/dl and/or a HDL-C of Ͻ 40 mg/dl for men and Ͻ 45 mg/dl for women. All patients were in stable health at the time of the study. None had an additional, secondary cause of dyslipidemia, such as renal, hepatic, or untreated thyroid disease. Three of five had a history of myocardial infarction, and all had multiple risk factors for CAD. All five patients had previously been treated with hypolipidemic drugs, but these were discontinued 1 month before beginning the study. Other medications were allowed if required by medical considerations (Table 1) . Exclusion criteria included the use of other drugs that might interfere with the metabolism of simvastatin. Patients were also excluded if they had a hypersensitivity to HMG-CoA reductase inhibitors, drank Ͼ 10 alcoholic beverages per week, had a serum creatinine of Ͼ 1.8 mg/dl, increased liver transaminases (more than twice the upper limit of normal), unstable CAD, recent ( Ͻ 3 months) myocardial infarction, angioplasty or cardiac bypass surgery, and uncontrolled hypertension.
Protocol
We conducted a randomized, double-blind, crossover study. There were two 7 week testing periods, one on active drug and one on placebo. The testing periods were performed in random order, with a 1 week washout period between treatments. Studies of apoB and TG metabolism were performed in the General Clinical Research Center (GCRC) at the Columbia University Medical Center (CUMC) at the end of each treatment period. Informed consent was obtained before each study period. The project received approval by the CUMC Institutional Review Board.
At the start of each study period, blood was drawn after a 12 h fast for the measurement of plasma lipids, routine chemistries, glucose, and glycosylated hemoglobin. Body weight and blood pressure were documented. After 4 weeks of each period, blood was drawn, and both VLDL and LDL were isolated by sequential ultracentrifugation as described previously (25, 28) . VLDL was radiolabeled with 125 I and LDL with 131 I by a modification of the iodine monochloride method (29, 30) . All procedures were carried out using sterile equipment, and the radiolabeled lipoproteins were passed through a 0.45 m filter for VLDL and a 0.22 m filter for LDL before injection into patients. At 5 weeks, subjects were admitted to the GCRC for 72 h. Fasting blood was obtained for the measurement of lipids and glucose. Nine hours before the start of the study (at midnight of the first day of hospitalization), patients began consuming a liquid diet (75% carbohydrate and 25% protein, at 60% of their total calorie requirements). They continued on this diet every 3 h for the 48 h of the VLDL turnover study. This dietary regimen, used in numerous studies, has been shown to provide stable plasma levels of cholesterol and TG (31, 32) . At 9 AM of the second day, subjects received an intravenous injection of 75 Ci of autologous 125 I-VLDL and 300 Ci of tritiated glycerol. The latter tracer was used to endogenously label VLDL-TG. Eighteen blood samples were collected over the next 48 h. After completion of the VLDL turnover study, 25 Ci of 131 I-LDL was injected intravenously, patients were switched back to their solid food diet, and several blood samples were obtained over the next 24 h. The patients were then discharged from the hospital, and blood samples were taken over the next 14 days while the subjects were outpatients. Potassium iodide supplements were started the evening before the VLDL injection and continued until 1 week after the last LDL sample was obtained.
Laboratory procedures
VLDL, IDL, and LDL were isolated from each of the 18 samples obtained after injection of 125 I-labeled VLDL by sequential ultracentrifugation in a 50.3 Ti fixed-angle rotor (25, 33) . ApoB in each lipoprotein fraction from each time point was then isolated using 1,1 Ј 3,3 Ј -tetramethylurea as described previously (34) .
ApoB specific activity in each sample was determined by measuring radioactivity and protein mass. LDL was isolated from the 16 samples obtained during the 2 week period after injection of 131 Ilabeled LDL, and apoB specific activity was determined directly by ␥ counting and protein determination (25, 33) . TG-glycerol, for analysis of VLDL-TG metabolism, was isolated using isopropyl alcohol and zeolite as described previously (26) . Samples were stored at 4 Њ C for 120 days to minimize contamination with 125 I. The tritium content of the samples was determined in a scintillation counter, correcting for any remaining 125 I.
Plasma cholesterol and TG levels were determined as the means of plasma concentration in nine time point specimens obtained during the turnover studies. Plasma HDL-C was determined after precipitation of apoB-containing lipoproteins with dextran sulfate magnesium chloride. VLDL-, IDL-, and LDL-lipid and -apoB concentrations were determined from samples obtained by ultracentrifugation during the turnover studies. ApoB mass was determined by specific radioimmunoassay (25, 33) . Cholesterol and TG concentrations were determined using enzymatic methods on a Hitachi 704 automated spectrophotometer.
Compartmental analysis
The apoB tracer data were fitted as reported by Arad, Ramakrishnan, and Ginsberg (25) . In each subject, the LDL-apoB specific activity data after the LDL-apoB tracer injection were fitted to a two-pool model. The VLDL-, IDL-, and LDL-apoB specific activity data from the VLDL-apoB tracer injection were then fitted, fixing the LDL kinetic parameters at the best estimates from the separate fit of the LDL-apoB tracer injection data. The model used is shown in Fig. 1A . The model was the simplest that could fit the data adequately; the deletion of any pool (e.g., a VLDL pool) or pathway (e.g., direct LDL synthesis) led to a sig- nificant worsening of the fits, whereas the addition of a pool (e.g., a fourth VLDL pool in the cascade) or pathway (direct IDL synthesis, conversion of the first two VLDL pools or the remnant VLDL to IDL or directly to LDL) resulted in no improvement to the fits. The TG tracer data were fitted by a single precursor pool and a two-pool VLDL configuration, shown in Fig. 1B (26) . The fitting was with POOLFIT, a pool-modeling program developed and used in our previous work.
Statistical analysis
Results are reported as means and standard deviations. Significance was tested at P ϭ 0.05 by paired t -tests.
RESULTS
As noted in Methods, baseline subject characteristics are shown in Table 1 . Table 2 shows the effects of simvastatin on plasma lipid levels. Individual subject values and group means are listed for placebo and treatment with simvastatin, 80 mg/day. On placebo, the patients had plasma TG levels ranging from the upper limits of normal to significant hypertriglyceridemia. All had low levels of HDL-C. There were significant reductions in both plasma total cholesterol ( Ϫ 42%) and TG ( Ϫ 37%) on 80 mg/day simvastatin therapy versus placebo. HDL-C levels increased by 21%. Table 3 presents the individual and group means for cholesterol and TG in each lipoprotein fraction isolated by sequential ultracentrifugation. There were dramatic and uniform reductions in all lipoprotein lipids in every subject during treatment with simvastatin compared with placebo. VLDL-C decreased by 53%, VLDL-TG by 39%, IDL-C by 59%, IDL-TG by 36%, LDL-C by 39%, and LDL-TG by 39%. Simvastatin treatment had similar effects on total plasma and lipoprotein-apoB levels ( Table 4 ) , with reductions in every subject. Plasma levels of total apoB declined by 44%, VLDL-apoB by 34%, IDL-apoB by 55%, and LDLapoB by 47%.
FCRs for VLDL-, IDL-, and LDL-apoB ( Table 5 ) were estimated by fitting the model shown in Fig. 1 to the specific activity data for each lipoprotein fraction. For VLDL-apoB, four subjects had increased FCRs and one had decreased FCRs, and there was a trend toward an increase in the mean FCR during simvastatin treatment for the group (2.0 Ϯ 0.80 to 2.7 Ϯ 1.3 h Ϫ 1 ; NS). The FCR for IDL-apoB increased in four of five subjects during simvastatin therapy, with a significant overall increase (0.82 Ϯ 0.30 to 1.40 Ϯ 0.16 h; P Ͻ 0.05). However, LDL-apoB FCR decreased in two subjects and increased in three subjects on simvastatin, with no significant change overall (0.75 Ϯ 0.41 vs. 0.81 Ϯ 0.40 h Ϫ 1 ; NS).
Rates of secretion into plasma for VLDL-apoB, IDL-apoB, and LDL-apoB are shown in Table 6 . Secretion rates were calculated by multiplying fractional catabolic rates by the plasma pool size of apoB in each lipoprotein. For VLDLapoB, treatment was associated with lower secretion rates in three subjects and increased rates in two subjects. Overall, there was no effect of simvastatin therapy on VLDL- IDL-apoB production was also unaffected by simvastatin therapy (4.5 Ϯ 1.4 vs. 3.6 Ϯ 0.9 mg/kg/h; NS). However, the effect of simvastatin therapy on LDL-apoB production was consistent: all subjects had a decline in production, with the mean rate on placebo of 27.3 Ϯ 13 mg/kg/day decreasing to 16.9 Ϯ 9 mg/kg/day on simvastatin (P Ͻ 0.05). The effects of simvastatin, 80 mg/day, on FCR and PR of VLDL-, IDL-, and LDL-apoB are summarized graphically in Fig. 2 .
The decrease in LDL-apoB production without a change in VLDL-apoB secretion into plasma suggested that less VLDL was converted to IDL and LDL during simvastatin treatment compared with placebo. This was not the case, however, as conversion rates of VLDL-apoB to LDL-apoB ( Table 7) actually increased in three of the five subjects, with no overall change in conversion for the group: conversion of VLDL-apoB to LDL-apoB was 31% with placebo and 43% during simvastatin therapy.
The PRs of LDL-apoB during both placebo and simvastatin administration, together with the calculated conversion rates, indicated that flux from VLDL to LDL was inadequate to account for LDL production in each study period. Indeed, our results demonstrated that a significant proportion of LDL-apoB flux was independent of VLDL secretion into plasma. Approximately 20 mg/kg/ day, ‫%57ف‬ of the calculated apoB flux through LDL during the placebo period, appeared to enter the plasma directly as apoB secreted into the LDL density range. During simvastatin treatment, the rate of secretion of apoB appearing directly as LDL decreased in every subject, with the mean during therapy of ‫9ف‬ mg/kg/day (P Ͻ 0.01 compared with placebo). However, this still constituted Ͼ50% of the flux of apoB through LDL ‫.)%56ف(‬ A summary of the effects of simvastatin on VLDL conversion to LDL, and the direct production of LDL, is presented graphically in Fig. 3 .
Because of the significant secretion into plasma of apoB-lipoproteins that appear directly in the LDL density range, it is necessary to examine the effect of simvastatin on total apoB secretion (the sum of VLDL secretion and direct LDL secretion). Simvastatin treatment resulted in a decrease in total apoB secretion rates in four subjects and an increase in one. The mean total apoB secretion rate during placebo treatment was 43.5 Ϯ 14 mg/kg/day, and this decreased to 30.7 Ϯ 8 mg/kg/day during simvastatin therapy, but this change was not statistically significant (Ϫ12.8 Ϯ 14; P ϭ 0.1).
We also determined the effect of simvastatin on the rates of secretion of VLDL-TG; these results are shown in Table 8 and Figure 4 . VLDL-TG FCR decreased in four of five subjects, with a trend toward a lower FCR on simvastatin (0.44 Ϯ 0.34 vs. 0.26 Ϯ 0.10; NS). VLDL-TG PR decreased in all five subjects, with a mean reduction of ‫%76ف‬ on simvastatin (59.9 Ϯ 62.8 vs. 19.6 Ϯ 10.9 mg/kg/h; P Ͻ 0.01). The decrease in VLDL-TG PR was associated with a 39% reduction in VLDL-TG levels during simvastatin compared with placebo. 
DISCUSSION
In this randomized, placebo-controlled, crossover study, treatment with 80 mg/day simvastatin produced significant and clinically relevant reductions of plasma total cholesterol, TG, and TG and cholesterol in VLDL, IDL, and LDL in patients with T2DM and dyslipidemia. Plasma and lipoprotein-apoB levels decreased significantly as well. HDL-C levels increased significantly during simvastatin treatment. These effects of statins on plasma levels of lipids, lipoproteins, and apoB are consistent with several other studies in patients with dyslipidemia and T2DM (35) (36) (37) .
Increased rates of secretion of VLDL-apoB and VLDL-TG have been demonstrated to be central features of the dyslipidemia present in individuals with insulin resistance and/or T2DM (10-12, 38, 39) . Our subjects had a mean VLDL-apoB secretion rate of ‫32ف‬ mg/kg/day, a mean LDL PR of ‫72ف‬ mg/kg/day, and a total apoB secretion rate of ‫44ف‬ mg/kg/day. Although we did not study normal subjects in this investigation, we have previously reported secretion rates of 15 and 13 mg/kg/day for VLDL-and LDLapoB, respectively, in normal individuals (40) , consistent with reports from other laboratories (41) . Thus, the present subjects with T2DM had, as expected, significantly increased rates of production of VLDL-and LDL-apoB. We also determined that these patients had significant secretion of LDL density particles directly into plasma. This is consistent with findings from our laboratory in previous studies of obese hypertriglyceridemic subjects (33) , in a patient with cholesteryl ester storage disease (42) , and in patients with combined hyperlipidemia (25) . The rates of VLDL-TG secretion in our subjects were also clearly increased compared with those in previous studies in normal subjects conducted by us (40) and others (43) . Increased VLDL-TG secretion has been a consistent finding in patients with T2DM (9, 44) .
The basis for the increased rates of apoB and TG secretion into plasma in subjects with T2DM appears to be a combination of factors related to insulin resistance and FA metabolism. First, several studies have shown that patients with T2DM have insensitivity to the insulin-mediated suppression of lipolysis (45, 46) and have, therefore, increased rates of FA flux in plasma and increased uptake of FA by the liver. Numerous studies with cultured liver cells indicate that FA availability in hepatocytes targets newly synthesized apoB for assembly with lipids and secretion, rather than degradation (47, 48) . Lewis and coworkers (49) have demonstrated in humans that an acute increase in plasma FA (resulting from intravenous infusions of intralipid and heparin) stimulates VLDL-apoB secretion. Second, FA synthesis in the liver, by de novo lipogenesis, can also be an important source of substrate for VLDL-TG in patients with insulin resistance and T2DM (50) (51) (52) . Recent studies from several laboratories using rodent models have suggested that hyperinsulinemia, a consequence of insulin resistance, can stimulate hepatic lipogenesis via increased expression of the gene for sterol response element binding protein 1c and subsequent upregulation of the expression of several lipogenic genes (53, 54) , even in an insulinresistant liver. Finally, insulin can acutely inhibit apoB secretion from cultured liver cells (55, 56) , and this action is lost in hepatocytes from insulin-resistant animals (57, 58) . In vivo studies of the effects of acute hyperinsulinemia in normal subjects suggest the inhibition of VLDL-apoB se- Fig. 3 . Percentage conversion VLDL to LDL-apoB and direct production of LDL-apoB. The proportion of VLDL-apoB (indicating the number of particles) that was converted to LDL-apoB and the rate of secretion of apoB-lipoproteins into plasma as LDL were estimated from the specific activity in apoB and the model shown in Fig. 1A . plac, placebo; Rx, simvastatin therapy. Values shown are means Ϯ SD. ** P Ͻ 0.01.
at PENN STATE UNIVERSITY, on February 23, 2013 www.jlr.org Downloaded from cretion (59, 60) , but this effect seems to be defective in obese individuals (59) and in subjects with T2DM (61) .
The uniform reductions in VLDL-, IDL-, and LDL-lipid and -apoB concentrations we observed during simvastatin treatment were associated with complex changes in the metabolism of those lipoproteins and VLDL-TG. Reductions in VLDL-TG and VLDL-apoB levels on simvastatin were accompanied by reductions in VLDL-TG secretion and no change in VLDL-apoB secretion, respectively. There were trends toward a decreased FCR for VLDL-TG and an increased FCR for VLDL-apoB on simvastatin therapy. Together, these data indicate that similar numbers of smaller VLDL particles, with less TG per particle, were secreted during simvastatin treatment compared with placebo treatment. Furthermore, although the fraction of TG removed per hour tended to be smaller during simvastatin treatment, smaller nascent VLDL particles tended to be more efficiently catabolized either to IDL and LDL or removed directly from plasma. Indeed, the nonsignificant overall increase in VLDL-apoB FCR was quantitatively similar to the decrease in VLDL-apoB concentration.
The reductions in LDL-C and LDL-apoB were associated with a decrease in the production of LDL-apoB but, unexpectedly, no change in LDL-apoB FCR, respectively. The decrease in LDL production was not the result of a decrease in the production of its typical precursor, VLDL, nor could lower LDL production be explained by changes in the proportion of VLDL that was converted to LDL. We did find, however, that the majority of LDL was produced independently of VLDL secretion: LDL was being secreted directly into plasma. Importantly, simvastatin treatment reduced direct LDL production by Ͼ50%.
How do our data compare with other studies of statin effects on apoB and TG metabolism in individuals with dyslipidemia (or combined hyperlipidemia)? At approximately the same time that the earliest studies reported that statins increased the FCRs of LDL-apoB in patients with familial hypercholesterolemia (23, 62, 63) , we demonstrated that lovastatin reduced the secretion of apoB-lipoproteins in a patient with cholesteryl ester storage disease and combined hyperlipidemia (42) ; LDL fractional clearance increased as well in that patient. We followed that report with a study of the effects of lovastatin in seven patients with dyslipidemia. In that study, secretion of apoB-lipoproteins into plasma was reduced significantly; VLDL-apoB secretion was not affected by lovastatin, but there was a significant reduction (44%) in the entry of LDL into plasma independent of VLDL secretion (25) . LDL fractional clearance was not affected by lovastatin treatment in those patients with dyslipidemia. By contrast, Vega and Grundy (64) reported that reductions in LDL-C levels with lovastatin in patients with mixed hyperlipidemia were associated with increases in LDL fractional clearance and no change in LDL production; VLDL metabolism was not studied. Cortner et al. (65) , however, observed reduced VLDL production during lovastatin therapy in patients with carefully defined familial combined hyperlipidemia, a disorder that is closely linked, in many families, with insulin resistance.
The studies described above used exogenously labeled VLDL and/or LDL. More recently, several groups have used stable isotopes of amino acids as precursors for studies of apoB-lipoprotein metabolism (66) . When study subjects had combined hyperlipidemia and low FCRs for LDL at baseline, atorvastatin, simvastatin (67) , and pravastatin (68) improved plasma lipid levels by increasing VLDL and LDL fractional clearance. In two studies in which baseline fractional clearance of LDL was similar to that in controls, patients with combined hyperlipidemia responded to atorvastatin (69) or lovastatin (70) with decreased production of apoB-lipoproteins with or without changes in the fractional clearance of apoB-lipoproteins from the circulation. In a third study of subjects with normal baseline LDL FCRs, pravastatin (71) increased the fractional clearance of apoB-lipoproteins. In recent studies by Watts and colleagues (72) (73) (74) , improved fractional clearance was associated with reductions in the levels of apoB-lipoproteins when atorvastatin was used to treat subjects with obesity and insulin resistance. On the other hand, Ouguerram et al. (27) , in the only study of patients with T2DM, reported that atorvastatin therapy was associated with both decreased VLDL-apoB secretion into plasma and normalization of a baseline low FCR of LDL in patients with T2DM. Overall, therefore, previous studies in patients with dyslipidemia, with or without T2DM, have produced variable results. An overview of these studies, however, suggests that when baseline FCRs of LDL were low, statins reduced plasma lipid levels by improving fractional clearance; when baseline PRs were high, irrespective of baseline FCRs, statins reduced the secretion of apoB-lipoproteins into plasma. LDL-apoB FCRs were normal or increased in our subjects during placebo treatment. The reason that statin therapy does not increase LDL-apoB FCR uniformly, as one might expect, is unclear. Our group did provide evidence that statin treatment can alter the apparent in vivo affinity of LDL for its receptor (75), but we could not determine the molecular or biochemical basis for that observation.
A possible explanation for the complex results we observed is that during placebo treatment, because of hepatic insulin resistance, the targeting of apoB for secretion is no longer tightly linked to TG secretion, so that even though there is increased hepatic TG availability and increased VLDL secretion, there is also the assembly and secretion of TG-poor, LDL-density lipoproteins. During simvastatin treatment, a reduction in the availability of hepatic TG for lipoprotein assembly leads to both the assembly and secretion of smaller VLDLs and increased apoB degradation (despite persistent insulin resistance). The latter change results in reduced secretion of LDL. Relevant to this proposed scheme are reports that statins may stimulate hepatic expression of the gene for the peroxisomal proliferator-activated receptor ␣ (PPAR␣) as well as its target genes, acyl-CoA oxidase and carnitine palmitoyltransferase (76). Martin et al. (77) suggested that statins activate PPAR␣ by inhibiting Rho signaling. Whatever the mechanism, such activation could increase fatty acid oxidation in the liver, resulting in less TG synthesis. On the other hand, fibrates, which are PPAR␣ agonists, are thought to act, at least in part, by reducing apoC-III production (78) and thereby improving the lipolysis of VLDL-TG (69, 74) . In our study, however, we did not see improvement in the FCR of either VLDL-TG or VLDL-apoB. Further studies will be required to fully understand the effects of statins on VLDL-TG metabolism.
In this study, treatment of patients with T2DM and dyslipidemia with 80 mg of simvastatin per day resulted in marked decreases of plasma cholesterol, TG, and apoB. These changes were associated with significant reductions in LDL-apoB PRs without effects on fractional catabolic rates. The decrease in LDL-apoB production was almost completely accounted for by reductions in the production of LDL independent of VLDL entry into plasma. Total production of apoB-lipoproteins decreased in four of the five subjects during simvastatin treatment. VLDL-TG secretion rates were also reduced during simvastatin treatment. Treatment with high-dose simvastatin corrected the dyslipidemia in these patients with T2DM by reducing the assembly and secretion of apoB-containing lipoproteins.
